Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

With interventions targeted towards improving maternal and child health along with quality and accessible health infrastructure, India has played a crucial role in the decline of global child mortality, especially in South Asia, according to a UN report today.

The UN Inter-agency Group for Child Mortality Estimation (UNIGME) Report 2025 highlighted that the country's sustained efforts in the last two decades in child health have led to significant outcomes in South Asia. They include:

• a 76 percent decline in under-five deaths since 1990 and a 68 percent drop since 2000
• the under-five death rate in the region fell from 92 deaths per 1,000 live births in 2000 to nearly 32 in 2024.

"India emerges as a leading global exemplar in the UN IGME 2025 report for accelerating child mortality reduction," JP Nadda, Union Health Minister, shared in a post on X.

"India’s focussed comprehensive approach on neonatal care has paved the way for eliminating preventable child deaths and securing healthy future for our children," he added.

Also read: 4.9 Million Children Died Before Age Five Worldwide In 2024: UN Report

India's Child Health Programs

In India, the UNIGME report showed that:

• under-five mortality rate reduced to 26.6 in 2024
• infant mortality fell to 23.3 per 1000 live births
• neonatal mortality rate dropped to 17

The report lauded India’s "continuum-of-care strategy" that has integrated sustained strengthening of a vibrant health system with commensurate expansion of its health infrastructure.

It also hailed demand-driven programmatic interventions in reducing preventable maternal and newborn mortality. These include:

• Janani Shishu Suraksha Karyakram (JSSK)
• Janani Suraksha Yojana (JSY), all of which are striving towards .
• Dedicated Maternal and Child Health (MCH) wings,
• Maternity Waiting Homes,
• Special Newborn Care Units (SNCUs),
• Newborn Stabilization Units (NBSUs),
• District Early Intervention Centres (DEICs).

Further, it noted that India’s commitment to improving newborn and child survival has also been reflected in continuous quality improvement initiatives such as the recently released guidelines on Facility-Based Newborn Care (FBNC) and

digital innovations such as Tele-SNCU (HUB & SPOKE model).

These efforts are complemented by hybrid skill-based learning modules on the safe and rational use of oxygen (including CPAP) and by the empowerment of mothers and caregivers to provide nurturing care to small and sick newborns.

"India is among the first few countries to set targets and release operational guidelines on Stillbirth Surveillance and response," the report said.

The UN noted that India’s experience shows that "sustained leadership, strategic investments, and strong collaboration with committed stakeholders have enabled a robust, scalable, and effective implementation framework targeted towards the achievement of the SDGs".

Finance Minister Nirmala Sitharaman has announced in the Parliament that India is planning to launch universal health coverage for all by 2033.

Addressing the Rajya Sabha, the Finance Minister stated that health insurance has become a priority area for the government, and informed that the sector has made significant progress, covering 58 crore lives in 2024–25, news agency PTI reported.

“Health insurance is a priority for this government. In fact, we are hoping that by 2033 we will have insurance cover for all,” Sitharaman said.

Growing Insurance Market

The FM added that the total health premium collections in the country reached Rs 1,17,505 crore in 2024–25. The health premiums under

• Public sector insurers accounted -- INR 42,420 crore
• Private insurers contributed INR 37,752 crore
• Standalone health insurers INR 37,331 crore

“Health insurance is now a clear priority with GST exemption on individual premiums, expansion of coverage, and strong regulatory push driving the momentum,” she said.

Health Insurance Under AB-PMJAY

Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), the world’s largest publicly funded health insurance scheme, launched in 2018, provides health cover of Rs 5 lakh per family per year. It provides secondary and tertiary care hospitalization to about 12 crore families, representing the bottom 40 per cent of the population.

The scheme was further expanded to cover 6 crore senior citizens of age 70 years and above, belonging to 4.5 crore families, irrespective of their socio-economic status.

Union Minister of State for Health and Family Welfare, Prataprao Jadhav, stated in a written reply in the Rajya Sabha that

till February 28:

• 43.52 crore Ayushman cards created
• 1.14 crore Ayushman Vay Vandana cards created for senior citizens
• 36,229 hospitals empaneled under AB-PMJAY -- 19,483 are public, and 16,746 are private hospitals

Further, the latest national master of Health Benefit Package provides cashless healthcare services for 1,961 procedures across 27 medical specialties.

“A total of 11.69 crore hospital admissions amounting to Rs. 1.73 lakh crore have been authorized under the scheme,” Jadhav said.

He added that more than 86 crore Ayushman Bharat Health Accounts (ABHA) have been created, and more than 90 Crore health records have been linked to patients’ ABHA.

In addition, Ayushman Bharat Digital Mission (ABDM) was launched in India in September 2021 to support the development of an integrated and citizen-centric national digital health ecosystem.

Till March 11, the progress made under ABDM includes:

• 86,64,46,563 - ABHA created for citizens
• 90,70,14,529 - Health records linked to the patient’s ABHA
• 2,56,542 - Facilities using ABDM-enabled software.

India’s Human Papillomavirus (HPV) vaccination drive that began a fortnight ago has already vaccinated nearly 3 lakh girls aged 14 years, according to the Union Health Ministry.

The nationwide free HPV vaccination campaign for girls aged 14 years was launched by Prime Minister Narendra Modi from Rajasthan's Ajmer on February 28.

“Within just a fortnight of its launch, nearly 3 lakh girls aged 14 years have already been vaccinated—marking an encouraging start to this critical public health initiative,” the health ministry said.

"The enthusiastic participation seen so far reflects growing awareness among parents, schools, and communities about the importance of early protection," it added.

Further, the Ministry noted that several states, including Madhya Pradesh, Andhra Pradesh, Tamil Nadu, Gujarat, Odisha, and Mizoram, have seen a significant uptake in the nationwide HPV vaccination campaign.

The initiative marked a decisive step towards eliminating cervical cancer through timely HPV vaccination.

Cervical cancer remains the second most common cancer among women in India. Nearly 80,000 new cases and over 42,000 deaths are reported annually in the country.

The Ministry said that despite examinations currently underway in many regions, the response to the campaign has remained strong, and the momentum is expected to accelerate significantly in the coming days.

“We are leaving no stone unturned to ensure that the daughters of the country are healthy and prosperous. The objective of this initiative is the prevention of cervical cancer," the Prime Minister, earlier wrote in a post on social media platform X.

The government has urged parents and guardians to support and encourage eligible girls to get vaccinated at the earliest.

HPV Vaccine in India

HPV vaccination is voluntary, and parental consent is mandatory before administration of the vaccine.

The single-dose Gardasil-4 vaccine is administered free of cost at government health facilities across all areas, including rural and underserved areas, and will be available even after the campaign ends.

The vaccine used is non-live and does not cause HPV infection. It is supported by more than 500 million doses administered globally since its introduction in 2006.

The vaccine is most effective when it is administered before exposure to HPV and before becoming sexually active. Young women aged 9 to 14 years show vaccine effectiveness of 74 to 93 per cent and this decreases with age.

• Girls aged 9 to 14 should get two doses of the vaccine 6 to 12 months apart
• Women aged 15 to 26 years can get three doses in 0, 2, and 6 months apart
• Adults aged 27 to 45 must get it after consultation with their healthcare provider

To avail the free HPV vaccine, visit any government health facilities including

Ayushman Arogya Mandirs- Primary Health Centres (PHCs